Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Joong-Won | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Bae, Si-Hyun | - |
dc.contributor.author | Paik, Seung Woon | - |
dc.contributor.author | Lee, Youn-Jae | - |
dc.contributor.author | Kim, Hwi Young | - |
dc.contributor.author | Lee, Han Chu | - |
dc.contributor.author | Han, Sang Young | - |
dc.contributor.author | Cheong, Jae Youn | - |
dc.contributor.author | Kwon, Oh Sang | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Kim, Bo Hyun | - |
dc.contributor.author | Hwang, Jaeseok | - |
dc.date.available | 2020-11-02T06:40:57Z | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.issn | 1600-0641 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2197 | - |
dc.description.abstract | Background & Aims Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed to compare clinical outcomes of sorafenib combined with concurrent conventional transarterial chemoembolization (cTACE) vs. sorafenib alone in patients with advanced HCC. Methods In this investigator-initiated, multicenter, phase III trial, patients were randomized to receive sorafenib alone (Arm S, n = 169) or in combination with cTACE on demand (Arm C, n = 170). Sorafenib was started within 3 days and cTACE within 7–21 days of randomization. The primary endpoint was overall survival (OS). Results For Arms C and S, the median OS was 12.8 vs. 10.8 months (hazard ratio [HR] 0.91; 90% CI 0.69–1.21; p = 0.290); median time to progression, 5.3 vs. 3.5 months (HR 0.67; 90% CI 0.53–0.85; p = 0.003); median progression-free survival, 5.2 vs. 3.6 months (HR 0.73; 90% CI 0.59–0.91; p = 0.01); and tumor response rate, 60.6% vs. 47.3% (p = 0.005). For Arms C and S, serious (grade ≥3) adverse events occurred in 33.3% vs. 19.8% (p = 0.006) of patients and included increased alanine aminotransferase levels (20.3% vs. 3.6%), hyperbilirubinemia (11.8% vs. 3.0%), ascites (11.8% vs. 4.2%), thrombocytopenia (7.2% vs. 1.2%), anorexia (7.2% vs. 1.2%), and hand-foot skin reaction (10.5% vs. 11.4%). A post hoc subgroup analysis compared OS in Arm C patients (46.4%) receiving ≥2 cTACE sessions to Arm S patients (18.6 vs. 10.8 months; HR 0.58; 95% CI 0.40–0.82; p = 0.006). Conclusion Compared with sorafenib alone, sorafenib combined with cTACE did not improve OS in patients with advanced HCC. However, sorafenib combined with cTACE significantly improved time to progression, progression-free survival, and tumor response rate. Sorafenib alone remains the first-line standard of care for patients with advanced HCC. Lay summary For patients with advanced hepatocellular carcinoma requiring sorafenib therapy, co-administration with conventional transarterial chemoembolization did not improve overall survival compared to sorafenib alone. Therefore, sorafenib alone remains the first-line standard of care for patients with advanced hepatocellular carcinoma. Clinical Trial Number: NCT01829035. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.jhep.2018.11.029 | - |
dc.identifier.scopusid | 2-s2.0-85062479564 | - |
dc.identifier.wosid | 000461333700013 | - |
dc.identifier.bibliographicCitation | Journal of Hepatology, v.70, no.4, pp 684 - 691 | - |
dc.citation.title | Journal of Hepatology | - |
dc.citation.volume | 70 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 684 | - |
dc.citation.endPage | 691 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | LIVER-CANCER | - |
dc.subject.keywordPlus | PORTAL-VEIN | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.subject.keywordAuthor | Transarterial chemoembolization | - |
dc.subject.keywordAuthor | Combination treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.